Shots:
- Novocure has reported CE Mark approval of Optune Lua for mNSCLC adults progressed on Pt-based regimen based on P-III (LUNAR) trial assessing the treatment vs PD-1/PD-L1 inhibitors/docetaxel alone; launch in Germany is expected in coming wks.
- Trial showed improved OS (1EP), with an mOS of 13.2 vs 9.9mos. with treatment vs PD-1/PD-L1 inhibitors/docetaxel, 18.5 vs 10.8mos. with Optune Lua & PD-1/PD-L1 inhibitor vs PD-1/PD-L1 inhibitor & 11.1 vs 8.7mos. with Optune Lua & docetaxel vs docetaxel
- As a CE Mark condition, TTFields concomitant willbe assessed with docetaxel in 180 mNSCLC pts over 12mos. to evaluate OS, comparing results to a matched control group treated with docetaxel alone
Ref: Novocure | Image: Novocure
Related News:- Novocure’s Optune Lua Receives the US FDA’s Nod for Treating Metastatic Non-Small Cell Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
